Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy.

Autor: Pasquali S; Molecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy. Electronic address: sandro.pasquali@istitutotumori.mi.it., Vallacchi V; Translational Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy., Lalli L; Translational Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy. Electronic address: luca.lalli@istitutotumori.mi.it., Collini P; Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy., Barisella M; Pathology Unit, ASST Fatebenefratelli Sacco, Milan, Italy., Romagosa C; Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Bague S; Pathology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain., Coindre JM; Department of Pathology, Institut Bergonié, 33000, Bordeaux, France; INSERM U1218 ACTION, Institut Bergonié, 33000, Bordeaux, France., Dei Tos AP; Surgical Pathology & Cytopathology Unit, Department of Medicine - DIMED, University of Padua, Padua, Italy., Palmerini E; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Quagliuolo V; Surgery Department, IRCCS Humanitas Research Hospital, Rozzano, Italy., Martin-Broto J; Oncology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain., Lopez-Pousa A; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quintí, 89, 08041, Barcelona, Spain., Grignani G; Medical Oncology Unit, Città della Salute e della Scienza Hospital, Turin, Italy., Blay JY; Centre Léon Bérard & Université Claude Bernard Lyon 1, Lyon, France., Beveridge RD; Department of Cancer Medicine, Hospital Universitari i Politècnic La Fe, Valencia, Spain., Casiraghi E; AnacletoLab, Department of Computer Science 'Giovanni degli Antoni', Università degli Studi di Milano, Milan, Italy., Brich S; Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy., Renne SL; Pathology Department, IRCCS Humanitas Research Hospital, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., Bergamaschi L; Translational Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy., Vergani B; School of Medicine and Surgery, University of Milano Bicocca, Monza, Italy., Sbaraglia M; Surgical Pathology & Cytopathology Unit, Department of Medicine - DIMED, University of Padua, Padua, Italy., Casali PG; Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy., Rivoltini L; Translational Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy. Electronic address: licia.rivoltini@istitutotumori.mi.it., Stacchiotti S; Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy., Gronchi A; Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy. Electronic address: alessandro.gronchi@istitutotumori.mi.it.

Publikováno v: EBioMedicine [EBioMedicine] 2024 Aug; Vol. 106, pp. 105220. Date of Electronic Publication: 2024 Jul 16.

Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study.

Autor: Ochenduszko S; Hospital Universitario Doctor Peset, Valencia, Spain., García Sanchez J; Centre Hospitalier de Wallonie Picarde, Tournai, Belgium., Fita MJJ; Instituto Valenciano de Oncología, Valencia, Spain., González-Barrallo I; Hospital Clínico Universitario de Valencia. INCLIVA, Valencia, Spain., Herrero Colomina J; Unidad del Cáncer de Gipuzkoa, OSID-Onkologikoa, San Sebastian, Spain., Mujika K; Unidad del Cáncer de Gipuzkoa, OSID-Onkologikoa, San Sebastian, Spain., Beveridge RD; Hospital Universitario y Politécnico La Fe, Valencia, Spain., Martínez SR; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain., Lafuente BS; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain., Tomas AC; Consorcio Hospital General Universitario de Valencia, Hospital General de Requena, Requena, Spain., Jaime AB; Consorcio Hospital General Universitario de Valencia, Valencia, Spain., Cerezuela Fuentes P; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain., Fra PL; Hospital Universitari Son Espases, Palma, Spain., Peeters AG; Hospital Universitari Son Espases, Palma, Spain., Meana García JA; Hospital General Universitario de Alicante, Alicante, Spain., García MAA; Hospital Marina Baixa, Villajoyosa, Spain., Altozano JP; Hospital Virgen de los Lirios, Alcoy, Spain., Cancela M; Hospital Virgen de los Lirios, Alcoy, Spain., Puchades AM; Hospital Universitario Doctor Peset, Valencia, Spain., Roca FF; Hospital Universitario Doctor Peset, Valencia, Spain., Maiques IM; Hospital Universitario Doctor Peset, Valencia, Spain.

Publikováno v: Pigment cell & melanoma research [Pigment Cell Melanoma Res] 2023 Sep; Vol. 36 (5), pp. 388-398. Date of Electronic Publication: 2023 May 27.

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.

Autor: Gounder MM; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY., Razak AA; Princess Margaret Cancer Center, Toronto, Ontario, Canada., Somaiah N; The University of Texas MD Anderson Cancer Center, Houston, TX., Chawla S; Sarcoma Oncology Center, Santa Monica, CA., Martin-Broto J; Fundacion Jimenez Diaz University Hospital, Madrid, Madrid, Spain., Grignani G; Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy., Schuetze SM; University of Michigan, Ann Arbor, MI., Vincenzi B; Policlinico Universitario Campus Bio-Medico, Roma, Italy., Wagner AJ; Dana-Farber Cancer Institute, Boston, MA., Chmielowski B; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA., Jones RL; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom., Riedel RF; Duke Cancer Institute, Durham, NC., Stacchiotti S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Loggers ET; Fred Hutchinson Cancer Research Center, Seattle, WA., Ganjoo KN; Stanford Cancer Institute, Stanford, CA., Le Cesne A; Institut Gustave Roussy, Villejuif, France., Italiano A; Institut Bergonié, Bordeaux, France., Garcia Del Muro X; Catalan Institute of Oncology, IDIBELL, University of Barcelona, Barcelona, Spain., Burgess M; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA., Piperno-Neumann S; Institut Curie, Paris, France., Ryan C; Oregon Health & Science University, Portland, OR., Mulcahy MF; The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL., Forscher C; Cedars-Sinai Medical Center, West Hollywood, CA., Penel N; Centre Oscar Lambret and Lille University, Lille, France., Okuno S; Mayo Clinic Rochester, Rochester, MN., Elias A; University of Colorado-Denver, Aurora, CO., Hartner L; University of Pennsylvania, Philadelphia, PA., Philip T; Northwell Health Physician Partners, New Hyde Park, NY., Alcindor T; McGill University Health Centre, Montreal, Quebec, Canada., Kasper B; Mannheim University Medical Center, Mannheim, Germany., Reichardt P; Helios Hospital Berlin-Buch, Berlin, Germany., Lapeire L; University Hospital Gent, Gent, Belgium., Blay JY; Centre Leon Berard, Lyon, France., Chevreau C; Institut Claudius Regaud-IUCT-O, Toulouse, France., Valverde Morales CM; Vall d'Hebron University Hospital, Barcelona, Spain., Schwartz GK; Columbia University Irving Medical Center, New York, NY., Chen JL; The Ohio State James Cancer Center, Columbus, OH., Deshpande H; Yale Cancer Center, New Haven, CT., Davis EJ; The Vanderbilt Clinic, Nashville, TN., Nicholas G; Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada., Gröschel S; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Heidelberg, Germany., Hatcher H; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., Duffaud F; La Timone University Hospital Center and Aix-Marseille University, Marseille, France., Herráez AC; Hospital Universitario Clínico San Carlos, Madrid, Spain., Beveridge RD; Hospital La Fe Valencia, Valencia, Spain., Badalamenti G; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy., Eriksson M; Skane University Hospital, Lund, Sweden., Meyer C; Johns Hopkins, Baltimore, MD., von Mehren M; Fox Chase Cancer Center, Philadelphia, PA., Van Tine BA; Washington University School of Medicine, St Louis, MO., Götze K; Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie Klinikum rechts der Isar der TU Muenchen, Marburg, Germany., Mazzeo F; UCL Saint-Luc, Brussels, Belgium., Yakobson A; Soroka University Medical Center, Be'er Sheva, Israel., Zick A; Faculty of Medicine, Hebrew University of Jerusalem, Israel; The Oncology Department, Hadassah Medical Center, Jerusalem, Israel., Lee A; The Christie NHS Foundation, Manchester, United Kingdom., Gonzalez AE; Catalan Institute of Oncology (ICO) Germans Trias I Pujol University Hospital, B-ARGO, Barcelona, Spain., Napolitano A; Policlinico Universitario Campus Bio-Medico, Roma, Italy., Dickson MA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY., Michel D; Karyopharm Therapeutics Inc, Newton, MA., Meng C; Karyopharm Therapeutics Inc, Newton, MA., Li L; Karyopharm Therapeutics Inc, Newton, MA., Liu J; Karyopharm Therapeutics Inc, Newton, MA., Ben-Shahar O; Karyopharm Therapeutics Inc, Newton, MA., Van Domelen DR; Karyopharm Therapeutics Inc, Newton, MA., Walker CJ; Karyopharm Therapeutics Inc, Newton, MA., Chang H; Karyopharm Therapeutics Inc, Newton, MA., Landesman Y; Karyopharm Therapeutics Inc, Newton, MA., Shah JJ; Karyopharm Therapeutics Inc, Newton, MA., Shacham S; Karyopharm Therapeutics Inc, Newton, MA., Kauffman MG; Karyopharm Therapeutics Inc, Newton, MA., Attia S; Mayo Clinic, Jacksonville, FL.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Aug 01; Vol. 40 (22), pp. 2479-2490. Date of Electronic Publication: 2022 Apr 08.

SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016).

Autor: Poveda A; Department of Medical Oncology, Instituto Valenciano de Oncología, IVO, Valencia, Spain., Martinez V; Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain., Serrano C; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain., Sevilla I; Investigación Clínica y Traslacional en Cáncer, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Málaga, Spain., Lecumberri MJ; Department of Medical Oncology, Complejo Hospitalario de Navarra, Navarre, Spain., de Beveridge RD; Musculoskeletal and Gastric Tumor Unit, Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain., Estival A; Department of Medical Oncology, Instituto Catalán de Oncología, ICO-Badalona, Hospital Germans Trias i Pujol, Badalona, Spain., Vicente D; Department of Medical Oncology, Hospital Universitario Virgen Macarena, Badalona, Spain., Rubió J; Department of Medical Oncology, Instituto Catalán de Oncología, ICO-Girona, Hospital Josep Trueta, Girona, Spain., Martin-Broto J; Department of Medical Oncology and Insituto de Biomedicina, IBIS, Hospital Universitario Virgen del Rocio, Av. Manuel Siurot, s/n, 41013, Sevilla, Spain. jmartin@mustbesevilla.org.

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2016 Dec; Vol. 18 (12), pp. 1221-1228. Date of Electronic Publication: 2016 Nov 28.

MRNIP/C5orf45 Interacts with the MRN Complex and Contributes to the DNA Damage Response.

Autor: Staples CJ; Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, Academic Unit of Molecular Oncology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK., Barone G; Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, Academic Unit of Molecular Oncology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK., Myers KN; Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, Academic Unit of Molecular Oncology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK., Ganesh A; Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, Academic Unit of Molecular Oncology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK., Gibbs-Seymour I; Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK., Patil AA; Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, Academic Unit of Molecular Oncology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK., Beveridge RD; Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, Academic Unit of Molecular Oncology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK., Daye C; Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, Academic Unit of Molecular Oncology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK., Beniston R; Biological Mass Spectrometry Facility biOMICS, University of Sheffield, Brook Hill Road, Sheffield S3 7HF, UK., Maslen S; Division of Cell Biology, Mass Spectrometry Group, The MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK., Ahel I; Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK., Skehel JM; Division of Cell Biology, Mass Spectrometry Group, The MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK., Collis SJ; Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, Academic Unit of Molecular Oncology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK. Electronic address: s.collis@sheffield.ac.uk.

Publikováno v: Cell reports [Cell Rep] 2016 Sep 06; Vol. 16 (10), pp. 2565-2575. Date of Electronic Publication: 2016 Aug 25.